Lite Strategy (LITS) AI Stock Analysis

• Market Cap: $76.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: -100.00%
• EPS Growth: -189.69%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 35,655,155
• 10 Day Avg. Volume: 1,152,811
• 30 Day Avg. Volume: 1,508,567
• PEG Ratio: -0.01
• Price to Book (P/B): 0.86
• Price to Sales (P/S): 0.44
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

MEI Pharma's overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock's outlook remains unfavorable.

Lite Strategy Business Overview & Revenue Model

Company Description

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

How the Company Makes Money

MEI Pharma makes money primarily through the development and commercialization of its oncology drug candidates. The company generates revenue from licensing agreements, milestone payments, and potential royalties related to the commercialization of its drug candidates. These agreements are often formed with larger pharmaceutical companies that have the resources to bring a drug to market. MEI Pharma's business strategy also involves strategic partnerships and collaborations that can provide funding and expertise for the continued development of its pipeline products. Additionally, the company may receive funding from government grants or research organizations to support its clinical trials and research activities.

Lite Strategy Financial Statement Overview

Summary

MEI Pharma faces significant financial challenges, particularly with revenue generation and profitability. The balance sheet shows limited leverage risks but declining asset base and equity levels. Cash flow issues highlight the need for operational efficiency improvements. The company's financial health is fragile, emphasizing the need for strategic adjustments to stabilize and grow.

Income Statement

The company shows volatility in revenue streams, with the latest TTM period reporting no revenue. The gross profit margin is negative due to a lack of revenue, and the TTM net profit margin is also negative, indicating a lack of profitability. Historical data shows fluctuating revenues with periods of positive EBIT and EBITDA margins, but the recent trend is concerning.

Balance Sheet

The balance sheet reveals a low debt burden, with a debt-to-equity ratio of 0, indicating no leverage risk. However, the equity ratio is declining, suggesting weakened financial stability. There is positive stockholders' equity, but the overall asset base has diminished over recent periods, raising concerns about resource sustainability.

Cash Flow

The cash flow statement highlights challenges in generating positive operating cash flow, which remains negative. The free cash flow is negative in the latest period, with the operating cash flow to net income ratio indicating inefficiencies. Prior periods show some positive cash flow from investing activities, but sustainability remains uncertain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	65.30M	48.82M	40.70M	25.54M	28.91M
Gross Profit	-664.00K	65.30M	48.82M	40.70M	24.13M	26.24M
EBITDA	-36.66M	25.82M	-36.38M	-75.16M	-60.14M	-25.59M
Net Income	-46.60M	17.78M	-31.84M	-54.45M	-41.31M	-47.17M
Balance Sheet
Total Assets	27.75M	41.38M	120.81M	177.84M	174.10M	209.73M
Cash, Cash Equivalents and Short-Term Investments	26.91M	38.34M	100.69M	153.25M	153.43M	182.63M
Total Debt	0.00	0.00	12.73M	9.64M	8.30M	0.00
Total Liabilities	2.87M	8.36M	96.19M	125.43M	132.74M	131.51M
Stockholders Equity	24.88M	33.02M	24.62M	52.41M	41.36M	78.22M
Cash Flow
Free Cash Flow	-43.44M	-50.48M	-52.52M	-49.23M	-32.67M	33.36M
Operating Cash Flow	-43.43M	-50.47M	-52.48M	-48.75M	-31.96M	34.26M
Investing Cash Flow	58.88M	49.14M	53.69M	6.89M	24.71M	-106.29M
Financing Cash Flow	-11.87M	-11.87M	-40.00K	49.05M	3.47M	74.78M

Lite Strategy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 2.13 is below the 20-day moving average (MA) of 2.54, below the 50-day MA of 3.67, and below the 200-day MA of 2.93, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 31.34 is Neutral, neither overbought nor oversold. The STOCH value of 16.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.

Lite Strategy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	54 Neutral	$11.13M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	46 Neutral	$24.05M	―	-127.48%	―	-95.87%	35.25%
PHIO	42 Neutral	$12.48M	―	-102.18%	―	―	85.26%
LITS	41 Neutral	$76.66M	―	-63.84%	―	-100.00%	-189.69%
COCP	40 Underperform	$13.82M	―	-110.56%	―	―	29.97%
INAB	34 Underperform	$9.85M	―	-165.56%	―	―	58.67%